Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2016 3
2017 1
2018 3
2020 1
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment.
Kalantarhormozi M, Hassanzadeh S, Rekabpour SJ, Ravanbod MR, Jafari E, Amini A, Dadgar H, Mahmoudpour M, Nabipour I, Jokar N, Assadi M. Kalantarhormozi M, et al. Among authors: ravanbod mr. World J Nucl Med. 2022 Aug 16;21(3):215-221. doi: 10.1055/s-0042-1755412. eCollection 2022 Sep. World J Nucl Med. 2022. PMID: 36060085 Free PMC article.
A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy.
Shahi F, Vafaeezadeh F, Ansarinejad N, Ahmadi A, Shahriari-Ahmadi A, Ghazizadeh A, Vahedian Ardakani H, Ravanbod MR, Seifi S, Foratyazdi M, Mousavi SA, Rajabi Vahid M, Rahimi H, Seghatoleslami M, Razavi SM, Pourkhani AH, Babakhani D, Anjidani N. Shahi F, et al. Among authors: ravanbod mr. Curr Ther Res Clin Exp. 2021 Dec 16;96:100659. doi: 10.1016/j.curtheres.2021.100659. eCollection 2022. Curr Ther Res Clin Exp. 2021. PMID: 35035631 Free PMC article.
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.
Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, Amini A, Keshmiri S, Dadgar H, Ahmadzadehfar H. Assadi M, et al. Among authors: ravanbod mr. World J Nucl Med. 2020 Feb 27;19(1):15-20. doi: 10.4103/wjnm.WJNM_20_19. eCollection 2020 Jan-Mar. World J Nucl Med. 2020. PMID: 32190017 Free PMC article.
14 results